Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Gils

Showing results (11-20 of 58) with videos related to

Pageof 6
Sort By:
Journal of Thrombosis and Haemostasis : JTH|September 17, 2013
Evaluation of the profibrinolytic properties of a bispecific antibody-based inhibitor against human and mouse thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1T Wyseure, A Gils, P J Declerck
Journal of Thrombosis and Haemostasis : JTH|July 23, 2003
Elucidation of a novel epitope of a substrate-inducing monoclonal antibody against the serpin PAI-1D Naessens, A Gils, G Compernolle, et al.
Journal of Thrombosis and Haemostasis : JTH|November 18, 2006
Announcing a TAFIa mutant with a 180-fold increased half-life and concomitantly a strongly increased antifibrinolytic potentialE Ceresa, M Peeters, P J Declerck, et al.
Journal of Thrombosis and Haemostasis : JTH|August 30, 2008
Bispecific targeting of thrombin activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 by a heterodimer diabodyJ Develter, N A Booth, P J Declerck, et al.
Journal of Thrombosis and Haemostasis : JTH|November 13, 2012
Plasmin and the thrombin-thrombomodulin complex both contribute to thrombin-activatable fibrinolysis inhibitor activation in whole blood model thrombiE Vercauteren, N J Mutch, P J Declerck, et al.
Biochimica Et Biophysica Acta|September 28, 1998
Characterization of plasminogen activator inhibitor 1 mutants containing the P13 to P10 region of ovalbumin or antithrombin III: evidence that the P13 residue contributes significantly to the active to substrate transitionA Gils, N Vleugels, K Tobback, et al.
Journal of Thrombosis and Haemostasis : JTH|June 3, 2008
Conformational (in)stability of rat vs. human activated thrombin activatable fibrinolysis inhibitorK Hillmayer, E Ceresa, R Vancraenenbroeck, et al.
Journal of Thrombosis and Haemostasis : JTH|July 2, 2013
Insights into thrombin activatable fibrinolysis inhibitor function and regulationJ H Foley, P Y Kim, N J Mutch, et al.
FEBS Letters|November 14, 1997
Identification of positively charged residues contributing to the stability of plasminogen activator inhibitor 1A Gils, J Lu, K Aertgeerts, et al.
Journal of Thrombosis and Haemostasis : JTH|October 19, 2013
Monoclonal antibodies targeting the antifibrinolytic activity of activated thrombin-activatable fibrinolysis inhibitor but not the anti-inflammatory activity on osteopontin and C5aF Semeraro, C T Ammollo, A Gils, et al.
Pageof 6

Showing results (11-20 of 58) with videos related to

Sort By:
Pageof 6
Journal of Thrombosis and Haemostasis : JTH|September 17, 2013
Evaluation of the profibrinolytic properties of a bispecific antibody-based inhibitor against human and mouse thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1T Wyseure, A Gils, P J Declerck
Journal of Thrombosis and Haemostasis : JTH|July 23, 2003
Elucidation of a novel epitope of a substrate-inducing monoclonal antibody against the serpin PAI-1D Naessens, A Gils, G Compernolle, et al.
Journal of Thrombosis and Haemostasis : JTH|November 18, 2006
Announcing a TAFIa mutant with a 180-fold increased half-life and concomitantly a strongly increased antifibrinolytic potentialE Ceresa, M Peeters, P J Declerck, et al.
Journal of Thrombosis and Haemostasis : JTH|August 30, 2008
Bispecific targeting of thrombin activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 by a heterodimer diabodyJ Develter, N A Booth, P J Declerck, et al.
Journal of Thrombosis and Haemostasis : JTH|November 13, 2012
Plasmin and the thrombin-thrombomodulin complex both contribute to thrombin-activatable fibrinolysis inhibitor activation in whole blood model thrombiE Vercauteren, N J Mutch, P J Declerck, et al.
Biochimica Et Biophysica Acta|September 28, 1998
Characterization of plasminogen activator inhibitor 1 mutants containing the P13 to P10 region of ovalbumin or antithrombin III: evidence that the P13 residue contributes significantly to the active to substrate transitionA Gils, N Vleugels, K Tobback, et al.
Journal of Thrombosis and Haemostasis : JTH|June 3, 2008
Conformational (in)stability of rat vs. human activated thrombin activatable fibrinolysis inhibitorK Hillmayer, E Ceresa, R Vancraenenbroeck, et al.
Journal of Thrombosis and Haemostasis : JTH|July 2, 2013
Insights into thrombin activatable fibrinolysis inhibitor function and regulationJ H Foley, P Y Kim, N J Mutch, et al.
FEBS Letters|November 14, 1997
Identification of positively charged residues contributing to the stability of plasminogen activator inhibitor 1A Gils, J Lu, K Aertgeerts, et al.
Journal of Thrombosis and Haemostasis : JTH|October 19, 2013
Monoclonal antibodies targeting the antifibrinolytic activity of activated thrombin-activatable fibrinolysis inhibitor but not the anti-inflammatory activity on osteopontin and C5aF Semeraro, C T Ammollo, A Gils, et al.
Pageof 6